Correction of subclinical ascorbate deficiency in patients receiving dialysis: effects on plasma oxalate, serum cholesterol, and capillary fragility.
Whole blood ascorbate, plasma oxalate, serum cholesterol, and capillary fragility were measured at monthly intervals for 3 mth in 7 patients receiving continuous ambulatory peritoneal dialysis and 4 receiving haemodialysis, to whom ascorbate supplements had not been prescribed for at least 12 mth. Ascorbate supplements, 25 mg/day, were prescribed for the first month and 50 mg/day for the second month; in the final month patients received no supplements. Whole blood ascorbate was below normal in 6/11 patients at the start of the study but was normal in 10/11 patients when taking ascorbate 50 mg/day. No significant changes in plasma oxalate were observed with these doses of ascorbate, and correction of ascorbate deficiency had no effect on serum cholesterol, mean cell volume, or the results of capillary fragility tests. In a supplementary study, ascorbic acid 500 mg/day was administered for 3 wk to 11 patients. This resulted in a significant rise in mean plasma oxalate from 30.3 (SEM 3.5) to 48.4 (SEM 20.3) mumol/l.
Tomson
C R
CR
Department of Medicine, University of Newcastle upon Tyne, UK.
Channon
S M
SM
Parkinson
I S
IS
McArdle
P
P
Qureshi
M
M
Ward
M K
MK
Laker
M F
MF
D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D001206:Ascorbic Acid Deficiency / Q000097:blood* / Q000188:drug therapy; D001663:Bilirubin / Q000097:blood; D002198:Capillary Fragility / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood*; D003404:Creatinine / Q000097:blood; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010070:Oxalates / Q000097:blood*; D006435:Renal Dialysis; D014280:Triglycerides / Q000097:blood
D006454:Hemoglobins; D010070:Oxalates; D014280:Triglycerides; D002784:Cholesterol; D003404:Creatinine; D001205:Ascorbic Acid; D001663:Bilirubin